Haplox Biotechnology Co.Ltd.
HAIC of FOLFOX(Haplox Biotechnology Co., Ltd.)은 Cholangiocarcinoma, Intrahepatic 표적 세포·유전자 치료로, Cholangiocarcinoma, Intrahepatic 영역에서 개발·상용화 중입니다. FDA 승인 또는 승인 단계 프로그램입니다. 대표 임상 효능: ORR 16% (ClinicalTrials.gov NCT04945720). 차별점: novel approach for predicting the early therapeutic response to HAIC-FOLFOX in patients with unresectable HCC.
Cholangiocarcinoma, Intrahepatic
Cholangiocarcinoma, Intrahepatic
Active
novel approach for predicting the early therapeutic response to HAIC-FOLFOX in patients with unresectable HCC
DNA damage repair responses in HCC cells, offering a promising therapeutic strategy to suppress HCC progression and enhance the ef
biomarkers, offering potential therapeutic targets to optimize clinical outcomes for patients with HCC
escape signatures in nonresponders, including a MECOM+ malignant subcluster
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
Haplox Biotechnology Co.Ltd.
HAIC of FOLFOX(Haplox Biotechnology Co., Ltd.)은 Cholangiocarcinoma, Intrahepatic 표적 세포·유전자 치료로, Cholangiocarcinoma, Intrahepatic 영역에서 개발·상용화 중입니다. FDA 승인 또는 승인 단계 프로그램입니다. 대표 임상 효능: ORR 16% (ClinicalTrials.gov NCT04945720). 차별점: novel approach for predicting the early therapeutic response to HAIC-FOLFOX in patients with unresectable HCC.
Cholangiocarcinoma, Intrahepatic
Cholangiocarcinoma, Intrahepatic
Active
novel approach for predicting the early therapeutic response to HAIC-FOLFOX in patients with unresectable HCC
DNA damage repair responses in HCC cells, offering a promising therapeutic strategy to suppress HCC progression and enhance the ef
biomarkers, offering potential therapeutic targets to optimize clinical outcomes for patients with HCC
escape signatures in nonresponders, including a MECOM+ malignant subcluster
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.